Circulating SIRT1 Increases After Intragastric Balloon Fat Loss in Obese Patients

Obesity Surgery

Volumn 26, Issue 6, 2016, Pages 1215-1220

  Mariani, Stefania ^a   Fiore, Daniela ^a   Persichetti, Agnese ^a   Basciani, Sabrina ^a   Lubrano, Carla ^a   Poggiogalle, Eleonora ^a   Genco, Alfredo ^a   Donini, Lorenzo Maria ^a   Gnessi, Lucio ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

BIB; Fat mass; Obesity; SIRT1; Weight loss

Indexed keywords

C REACTIVE PROTEIN; FAT; FIBRINOGEN; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN; PROPOFOL; SIRTUIN 1; TRIACYLGLYCEROL; SIRT1 PROTEIN, HUMAN;

ADULT; ARTICLE; BODY COMPOSITION; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DUAL ENERGY X RAY ABSORPTIOMETRY; ELISA KIT; FAT BODY; FAT MASS; FEMALE; FIBRINOGEN BLOOD LEVEL; GASTRIC BALLOON; GLUCOSE BLOOD LEVEL; HUMAN; LOW CALORY DIET; MALE; METABOLIC SYNDROME X; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE; WEIGHT REDUCTION; X RAY SYSTEM; ADOLESCENT; BLOOD; MIDDLE AGED; POSTOPERATIVE PERIOD; YOUNG ADULT;

ADOLESCENT; ADULT; BODY COMPOSITION; DIET, REDUCING; FEMALE; GASTRIC BALLOON; HUMANS; MALE; MIDDLE AGED; OBESITY; POSTOPERATIVE PERIOD; SIRTUIN 1; TRIGLYCERIDES; WEIGHT LOSS; YOUNG ADULT;

EID: 84940703146     PISSN: 09608923     EISSN: 17080428     Source Type: Journal    
DOI: 10.1007/s11695-015-1859-4     Document Type: Article

References (27)

1. Herranz D, Serrano M. SIRT1: recent lessons from mouse models. Nat Rev Cancer. 2010;10(12):819–23.
2. Herranz D, Munoz-Martin M, Canamero M, et al. Sirt1 improves healthy ageing and protects from metabolic syndrome-associated cancer. Nat Commun. 2010;1:3–17.
3. Saunders LR, Verdin E. Sirtuins: critical regulators at the crossroads between cancer and aging. Oncogene. 2007;26(37):5489–504.
4. Mariani S, Fiore D, Basciani S, Persichetti A, Contini S, Lubrano C, et al. Plasma levels of SIRT1 asso ciate with non-alcoholic fatty liver disease in obese patients. Endocrine. 2015;49(3):711–6.
5. Xu F, Gao Z, Zhang J, et al. Lack of SIRT1 (mammalian sirtuin 1) activity leads to liver steatosis in the SIRT1+/− mice: a role of lipid mobilization and inflammation. Endocrinology. 2010;151(6):2504–14.
6. Purushotham A, Schug TT, Xu Q, et al. Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metab. 2009;9(4):327–38.
7. Gillum MP, Kotas ME, Erion DM, et al. SirT1 regulates adipose tissue inflammation. Diabetes. 2011;60(12):3235–45.
8. Cho KW, Lumeng CN. SirT1: a guardian at the gates of adipose tissue inflammation. Diabetes. 2011;60(12):3100–2.
9. Qiang L, Wang L, Kon N, et al. Brown remodeling of white adipose tissue by SirT1-dependent deacetylation of Pparγ. Cell. 2012;150(3):620–32.
10. Xu F, Burk D, Gao Z, et al. Angiogenic deficiency and adipose tissue dysfunction are associated with macrophage malfunction in SIRT1-/- mice. Endocrinology. 2012;153(4):1706–16.
11. Picard F, Kurtev M, Chung N, et al. Machado De Oliveira R, et al. Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature. 2004;429(6993):771–6.
12. Kitada M, Kume S, Takeda-Watanabe A, et al. Calorie restriction in overweight males ameliorates obesity-related metabolic alterations and cellular adaptations through anti-aging effects, possibly including AMPK and SIRT1 activation. Biochim Biophys Acta. 2013;1830(10):4820–7.
13. Genco A, Maselli R, Frangella F, Cipriano M, Forestieri P, Delle Piane D, et al. Intragastric balloon for obesity treatment: results of a multicentric evaluation for balloons left in place for more than 6 months. Surg Endosc. 2015;29:2339–43.
14. Conference NIH. Gastrointestinal surgery for severe obesity. Consensus development conference panel. Ann Intern Med. 1991;115(12):956–61.
15. Genco A, Cipriano M, Bacci V, et al. BioEnterics Intragastric Balloon (BIB): a short-term, double-blind, randomised, controlled, crossover study on weight reduction in morbidly obese patients. Int J Obes (Lond). 2006;30(1):129–33.
16. Mariani S, Fiore D, Barbaro G, et al. Association of epicardial fat thickness with the severity of obstructive sleep apnea in obese patients. Int J Cardiol. 2013;167(5):2244–9.
17. Lubrano C, Saponara M, Barbaro G, et al. Relationships between body fat distribution, epicardial fat and obstructive sleep apnea in obese patients with and without metabolic syndrome. PLoS One. 2012;7(10), e47059.
18. Cummins TD, Holden CR, Sansbury BE, et al. Metabolic remodeling of white adipose tissue in obesity. Am J Physiol Endocrinol Metab. 2014;307(3):262–77.
19. Quiñones M, Al-Massadi O, Fernø J, et al. Cross-talk between SIRT1 and endocrine factors: effects on energy homeostasis. Mol Cell Endocrinol. 2014;397(1-2):42–50.
20. Pfluger PT, Herranz D, Velasco-Miguel S, et al. Sirt1 protects against high-fat diet-induced metabolic damage. Proc Natl Acad Sci U S A. 2008;105(28):9793–8.
21. Pang W, Wang Y, Wei N, et al. Sirt1 inhibits akt2-mediated porcine adipogenesis potentially by direct protein-protein interaction. PLoS One. 2013;8(8), e71576.
22. Song YS, Lee SK, Jang YJ, et al. Association between low SIRT1 expression in visceral and subcutaneous adipose tissues and metabolic abnormalities in women with obesity and type 2 diabetes. Diabetes Res Clin Pract. 2013;101(3):341–8.
23. Pedersen SB, Olholm J, Paulsen SK, et al. Low Sirt1 expression, which is upregulated by fasting, in human adipose tissue from obese women. Int J Obes (Lond). 2008;32(8):1250–5.
24. Moschen AR, Wieser V, Gerner RR, et al. Adipose tissue and liver expression of SIRT1, 3, and 6 increase after extensive weight loss in morbid obesity. J Hepatol. 2013;59(6):1315–22.
25. Kotas ME, Gorecki MC, Gillum MP. Sirtuin-1 is a nutrient-dependent modulator of inflammation. Adipocyte. 2013;2(2):113–8.
26. Baksi A, Kraydashenko O, Zalevkaya A, et al. A phase II, randomized, placebo-controlled, double-blind, multi-dose study of SRT2104, a SIRT1 activator, in subjects with type 2 diabetes. Br J Clin Pharmacol. 2014;78(1):69–77.
27. Aasen G, Fagertun H, Halse J. Regional fat mass by DXA: high leg fat mass attenuates the relative risk of insulin resistance and dyslipidaemia in obese but not in overweight postmenopausal women. Scand J Clin Lab Invest. 2008;68(3):204–11.